Phase III maternal RSV vaccine study in pregnant women to prevent infant RSV lower respiratory tract illness

Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) and pulmonary infection comparing RSV MAT vaccine with Placebo (2 arms). Primary endpoint: Number of infant participants with medically assessed, RSV-associated lower respiratory tract illness up to 6 months of age. Started Nov 2020; status: completed.